Bibliography
- HARRISON PJ, OWEN MJ: Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet (2003) 361(9355):417–419.
- HARGREAVES R: Imaging substance P (NK1) in the living human brain using positron emission tomography. I Clin. Psychiatry(2002) 63:18–24.
- KIRKPATRICK B, BUCHANAN RW, ROSS DE, CARPENTER WT: A separate disease within the syndrome of schizophrenia. Arch. Gen. Psychiatry (2001) 58:165–171.
- DUMAN RS, MALBERG J, THOME J:Neural plasticity to stress and antidepressant treatment. Biol. Psychiatry (1999) 46:1181–1191.
- MOORE RY, SPEH JC, LEAK RK: Suprachiasmatic nucleus organization. Cell Tissue Res. (2002) 309:89–98.
- WANG GK, SEHGAL A: Signaling components that drive circadian rhythms. CLIFF. Opin. Neurobiol (2002) 12(3):331–338.
- CHENG MY, BULLOCK CM, LI C et al: Prokineticin 2 transmits the behavioural circadian rhythm of the suprachiasmatic nucleus. Nature (2002) 417(6887):405–410.
- BOROWSKY B, DURKIN MM, OGOZALEK K et al.: Antidepressant, amdolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist. Nat. Med. (2002) 8(8):825–830.
- SERRADEIL-LE GAL C, WAGNON J, SIMIAND J et at. Characterisation of (25, 4R) 1 [5 chloro-1 - [(2, 4-dimethoxyphenyl)sulfonyl] 3 (2 methoxy-pheny1)-2-oxo-2,3-dihydro 1H indol 3 yl] 4-hydroxy-N,N-dimethy1-2-pyrrolodine carboxamide (SSR149415), a selective and orally active vasopressin Vlb receptor antagonist. Pharinacol Exp. The]: (2002) 300:1122–1130.
- NIC DHONNCHADHA BA, BOURIN M, HASCOET M: Anxiolytir-like effects of 5-HT2 ligands on three mouse models of anxiety. Behav. Brain Res. (2003) 140(1-2):203–214.
- JONSSON EG, FLYCKT L, BURGERT E et al.: Dopamine D3 receptor gene Ser9Gly variant and schizophrenia: association study and meta-analysis. Psychiatr. Genet. (2003) 13(1):1–12.
- COYLE JT, TSAI G, GOFF DC: Ionotropic glutamate receptors as therapeutic targets in schizophrenia. Carr: Drug Target CNS Neurol Disord. (2002) 1(2):183–189.
- GRILLON C, CORDOVA J, LEVINE LR, MORGAN CA 3rd: Anxiolytir effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans. Psychopharmacology (Berl) (2003) 168:446–454.